Roche Holding AG (RHHBY)
-OTC Markets 63.53 May 20, 3:59PM EDT|Pre-Market
:
NaN
| Prev Close: | 63.53 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 66.40 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 38.63 - 64.48 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 494,940 |
|---|
| Market Cap: | 215.61B |
|---|
| P/E (ttm): | 21.26 |
|---|
| EPS (ttm): | 2.99 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Will ASCO Unlock Big Value in This Cancer Drug Class?at Motley Fool(Sat, May 18)
- Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buyat Seeking Alpha(Fri, May 17)
- Good News for Roche's TarcevaZacks(Thu, May 16)
- Pipeline Progress at GileadZacks(Thu, May 16)
- Melanoma Treatment Harnesses Immune System to Combat Cancer Cellsat New York Times(Wed, May 15)
- Cancer Meeting Highlights the Good and Bad of the Immune Systemat Motley Fool(Wed, May 15)
- Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood CancerBusiness Wire(Wed, May 15)
- ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Upat TheStreet(Wed, May 15)
- ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumorsat TheStreet(Wed, May 15)
- Nektar Posts Wider Loss, Maintains ViewZacks(Wed, May 15)
- Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCOBusiness Wire(Wed, May 15)
- FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung CancerBusiness Wire(Tue, May 14)
- Companies Invest in Antibodies That Fight Tumorsat Motley Fool(Mon, May 13)
- Lilly Scraps Oncology CandidateZacks(Mon, May 13)
- Tackling Cancer: Endometrial Cancer's Biggest Current & Upcoming Playersat Motley Fool(Sat, May 11)
Key Statistics
| Forward P/E (1 yr): | 15.20 |
|---|
| P/S (ttm): | 4.24 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.91 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | 2.31 |
|---|
Business Summary
Roche Holding AG operates in the fields of pharmaceuticals and diagnostics worldwide. It discovers, develops, and provides diagnostic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, ...
View More 
0.12%